Autoimmune Dysregulation in Pigmentary Glaucoma

This study has been completed.
Sponsor:
Information provided by:
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00280345
First received: January 19, 2006
Last updated: July 8, 2011
Last verified: July 2011
  Purpose

Based on these recent observations and findings in this new animal model of pigmentary glaucoma in the DBA/2J mouse, we propose that immune system abnormalities in the anterior chamber may play a possible role in the development of pigmentary glaucoma and possibly primary open-angle glaucoma (POAG) in humans.


Condition Intervention
Pigmentary Glaucoma
Primary Open Angle Glaucoma
Cataract
Procedure: Trabeculectomy
Procedure: Trabeculectomy and cataract surgery
Procedure: Cataract surgery

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Autoimmune Dysregulation in Pigmentary Glaucoma

Resource links provided by NLM:


Further study details as provided by University of Oklahoma:

Primary Outcome Measures:
  • Autoimmune Dysergulation in Pigmentary Glaucoma [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: February 2006
Study Completion Date: May 2009
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Trabeculectomy
    A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
    Procedure: Trabeculectomy and cataract surgery
    A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
    Procedure: Cataract surgery
    Removal of the cataract from the eye
Detailed Description:

The aim is to establish, through tissue and aqueous analysis of patients with pigmentary glaucoma, POAG and normal controls, that markers for anterior chamber autoimmune dysfunction occur in significantly different amounts in patients with these conditions when compared to normal controls. We also will attempt to establish, through proven methodologies of tissue gene expression, that the source of these differences in markers, notably PEDF and IL-18, is from the uveal tissues of the anterior chamber, most importantly the iris and possibly the trabecular meshwork as well.

The actual etiology at the cellular level of elevated intraocular pressure and the development of pigmentary glaucoma is not well understood in humans. If anterior chamber immune dysfunction were shown to be an important factor in the development of this disease in humans, which apparently is demonstrated by the DBA/2J mouse, it would lead to an important area of further investigation and possible novel approaches in treating or preventing this disease in humans.

We hypothesize that in patients with pigmentary glaucoma, the amount of PEDF in the aqueous is significantly reduced while IL-18 is significantly elevated when compared to the aqueous of normal controls. In patients with POAG, we hypothesize similar results for PEDF, although significantly less reduction of PEDF when compared to the pigmentary glaucoma patients may be an interesting finding as well. With regard to IL-18, it is possible that amounts would be significantly elevated in the pigmentary glaucoma patients when compared to both normal controls and POAG patients. In view of the results from the DBA/2J mouse model, we hope to determine whether expression of PEDF could be down regulated in the iris and/or trabecular meshwork of pigmentary glaucoma patients when compared to POAG patients and whether IL-18 expression in these tissues could be up regulated in pigmentary glaucoma patients when compared to POAG patients.

Such findings would strongly suggest that anterior chamber immune abnormalities play a role in the etiology of pigmentary glaucoma in humans. It already has been suggested that decreased amounts and expression of PEDF are found in patients with glaucoma and other neurodegenerative diseases of the eye. However, the source of the decreased expression has not been identified. If IL-18 production is elevated in pigmentary glaucoma and is up regulated in the anterior chamber structures of the eye in human patients with the disease, this also would be highly suggestive that localized anterior chamber immune dysfunction plays a role in the development of this disease.

Depending on our findings, additional investigations of autoimmune dysregulation in pigmentary glaucoma (and perhaps other secondary glaucomas) may help determine the predictive value of such markers in identifying whether or not patients with pigment dispersion syndrome develop glaucomatous damage.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Patients in the study will be between 18 and 85 years old. To prevent any possibility that previous manipulation of the iris and uveal structures may affect results of the assays, patients with any previous intraocular surgery or laser iridotomies will be excluded. Patients who have undergone laser trabeculoplasty within 90 days of surgery also will be excluded. In the normal controls undergoing cataract surgery, patients with signs of pigment dispersion syndrome or exfoliation syndrome without glaucoma will be excluded from the study.

Additional Inclusion Criteria:

  1. In the glaucoma patients, visual field and/or optic disc changes characteristic of glaucoma.
  2. Ability to comprehend the information describing the clinical study.
  3. Ability to provide signed and dated IRB-approved informed consent (ICF) for the study.

Exclusion Criteria:

  1. Any clinically significant uncontrolled medical condition(s) that might, in the investigators' opinion, interfere with the assessment.
  2. Use of corticosteroids within 3 months prior to surgery.
  3. Use of systemic anti-metabolites within 6 weeks prior to surgery.
  4. Use of any investigational drug within 4 weeks prior to surgery.

Specific to the study eye exclusions:

  1. History of non-iatrogenic uveitis or active uveitis.
  2. Discernible congenital abnormality of the anterior chamber structures.
  3. Neovascular, uveitic, traumatic, or infantile glaucoma.
  4. Proliferative or severe non-proliferative diabetic retinopathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00280345

Locations
United States, Oklahoma
Dean A. McGee Eye Institute
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: STEVEN R SARKISIAN, MD Dean A. McGee Eye Institute
  More Information

No publications provided

Responsible Party: Autoimmune Dysregulation in Pigmentary Glaucoma, Dean A. McGee Eye Institution
ClinicalTrials.gov Identifier: NCT00280345     History of Changes
Other Study ID Numbers: Pigmentary Glaucoma
Study First Received: January 19, 2006
Last Updated: July 8, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Oklahoma:
pigmentary glaucoma
primary open angle glaucoma
cataract
trabeculectomy
cataract surgery

Additional relevant MeSH terms:
Glaucoma
Cataract
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Lens Diseases

ClinicalTrials.gov processed this record on September 18, 2014